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Abstract 
Pharmacokinetics focuses on the question whether a drug actually reaches its target in therapeutic 
concentrations or accumulates elsewhere, potentially causing toxicological or unpredictable side effects. 
We determined tissue distribution of gemcitabine, an antimetabolite, and crizotinib, a tyrosine-kinase 
inhibitor targeted against the anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition 
factor (c-Met) receptors, in a validated orthotopic mouse model for pancreatic cancer. Mice with 
pancreatic cancer were treated with either oral crizotinib at 25 mg/kg, gemcitabine at 100 mg/kg or with 
their combination. Two hours after the last gemcitabine dose mice were sacrificed and all available 
blood/organs/tissues were sampled. Tissue was subsequently analyzed for drug concentrations using a 
validated liquid chromatography-mass spectrometry (LC-MS/MS) technique. In whole blood gemcitabine 
was about 1.0 µM and crizotinib 2.4 µM in the single treatment, whereas in the combination crizotinib 
increased the levels of gemcitabine. Crizotinib was found in all major tissues, being highest in the intestine. 
Comparison of crizotinib alone to the gemcitabine-crizotinib combination showed that crizotinib tissue 
concentrations were 3-6 fold lower in liver, lung, kidney and spleen, 30-fold lower in the skin, heart and 
pancreas and 200-fold lower in the brain. Tissue gemcitabine was highest in spleen and skin, being about 5-
10 fold higher than in the other tissues, including brain, which still had a relatively high accumulation. In 
conclusion, both gemcitabine and crizotinib accumulate at clinically active but variable levels in tissues, 
possibly relating to the effects exerted by these drugs.  
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Introduction 
Pharmacokinetics usually focuses on the behavior of a single drug in plasma in order to obtain 
information on its uptake, distribution and elimination [1]. In cancer patients this information can give 
insight in the mechanism of action, the relationship between dose, systemic concentration and biological 
effect (beneficial or otherwise) [2]. However, limited or insufficient attention is usually given to the 
question whether the drug actually reaches its target (the tumor) in therapeutic concentrations or 
accumulates in normal tissues potentially leading to toxicity. Usually drug interactions of combinations 
receive limited interest. Earlier we investigated the interaction between gemcitabine and crizotinib 
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(Figure 1) and demonstrated a synergistic effect between the drugs in in vitro and in vivo models of 
pancreatic ductal adenocarcinoma (PDAC) [3]. In the present study we aimed to analyze their interaction in 
normal tissues, in order to determine whether this information can give an explanation for toxic side effects 
seen with these drugs in patients.   
Crizotinib is registered for the treatment of non-small cell lung cancer that expresses the abnormal 
EML4-ALK fusion gene, and has been evaluated for use with tumors expressing high c-Met [4-6]. In turn, 
gemcitabine is standard first line treatment in a wide range of carcinomas including non-small cell lung 
cancer, pancreatic cancer, bladder cancer and breast cancer [7]. In this paper we describe the tissue 
distribution of both crizotinib and gemcitabine, given alone or together in a patient-derived orthotopic 
mouse PDAC model. 
 
Figure 1. Structural formulae of crizotinib (A) and gemcitabine (B). 
Model and methods 
Mouse model 
Orthotopic primary-PDAC mouse models were developed as reported by Avan et al. [3] by implantation 
of primary tumor cells into 6-8 week old female athymic nude mice (Harlan, Host, The Netherlands). Tumor 
growth was monitored via bioluminescence, as described previously [3]. The mice were treated with oral 
crizotinib at 25 mg/kg, or gemcitabine at 100 mg/kg intraperitoneally 4 times at 3-day intervals. The third 
group received a combination of both drugs. Blood was taken via the tail vein at 1 and 2 h after drug 
administration. Thereafter mice were sacrificed and all available organs/tissue was sampled. Sampled tissue 
was immediately frozen in liquid nitrogen and stored at -80 °C. 
Drug analysis and equipment 
Tissue and whole blood concentrations of gemcitabine and crizotinib were determined by adaptation of 
a validated liquid chromatography-mass spectrometry (LC-MS/MS) methodology previously reported [8,9] 
using a Sciex API3000 mass spectrometer coupled with a Dionex Ultimate 3000 capillary LC system. 
Precision, accuracy, robustness and stability were established for crizotinib and gemcitabine prior to tissue 
analysis in whole blood, plasma, serum and cell culture medium [8]. Parameters were determined with 
software “Analyst” version 6.2 (Sciex BV, Breda) and DMSlink ver 2.10 (Thermo Scientific - Dionex, Breda). 
Whole blood, plasma and serum were extracted by adding 20 µl whole blood aliquots to 80 µl 
acetonitrile and sonicating for 15 seconds. After centrifugation at 2500 g for 10 minutes / 4 °C, the 
supernatant was taken and analyzed by LC-MS/MS. Tissue sample preparation was performed by taking 
triplicate portions of each tissue (5-30 mg), weighed into 1.5 ml cryogenic vials which were subsequently 
desiccated using the freeze drying processes for 48 h. Samples were then homogenized for 10 min with 
acetonitrile: water (5:1), sonicated and centrifuged. The subsequent supernatant was then analyzed by LC-
MS/MS.  
(A) (B) 
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Crizotinib optimization 
Crizotinib analysis was optimized for mass spectroscopic detection as described earlier for tyrosine 
kinase inhibitors. Briefly, 1 µg/ml solution was infused at 3 µl per min into the turbo ionisation source, the 
parent ion for crizotinib (MW-449) was established as 450, 451 and 452 amu with characteristic pattern of a 
chlorine containing molecule (Figure 2A). The major fragment of the 450 amu response was 259.9 (Figure 
2A). Mass spectrometric parameters for the transition quadrupole pairing (Q1/Q3) of 450.0/259.1 are: 
declustering potential (DP), 61 V; focusing potential, 270 V; entrance potential, 10 V; collision energy, 31 V; 
cell exit potential, 18 V. 
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Figure 2. Ionisation spectrum and chromatography of crizotinib, gemcitabine and of the internal control 
deoxycytidine. (A) Ionisation spectrum of the parent compound (crizotinib) and the product ion spectrum of 
the [M+H]
+
 ion for crizotinib in chromatographic mobile phase, consisting of acetonitrile, methanol, isopropyl 
alcohol and aqueous ammonium acetate at pH 7.80. (B) Chromatography of crizotinib, gemcitabine and 
deoxycytidine. (C) Linearity of crizotinib analysis in mouse and human whole blood. 
 
Extraction and chromatography 
Crizotinib chromatography was performed using the optimized chromatographic system for the multiple 
tyrosine kinase inhibitors (Figure 2B) [8]. Under these set conditions crizotinib exhibited less sensitivity 
G.J. Peters et al.  ADMET & DMPK 4(4) (2016) 327-334 
330  
when compared to erlotinib, sunitinib and gefitinib. However, the crizotinib assay was linear up to 30 µg/ml 
in both plasma and serum (r2 = 0.986, n= 10), and reproducible over a 3 day period. Crizotinib was more 
soluble in aqueous solutions than other reported TKIs. For whole blood the extraction was best performed 
in reverse, where the 20 µl sample of whole blood was pipetted directly into round bottomed 96 well 
already containing 80 µl of acetonitrile. This ensured each sample was homogeneously mixed prior to 
centrifugation and transfer of the supernatant for LC-MS/MS analysis.   
Linearity 
Linear regression for whole blood preparations was similar to plasma / serum / cell culture medium in 
the 1 – 5000 ng/ml and was acceptable (r2>0.98). The standard error was within ± 15 % for each calibration 
point used. The limit of quantitation for crizotinib was 50 ng/ml, Due to lack of stock mouse whole blood 
preparations of human whole blood were compared to mouse whole blood standard curves. No difference 
was observed in the linear regression parameters determined (Figure 2C), hence human whole blood was 
used as an alternative stock matrix for the samples to be analyzed. 
To limit the standard requirements per analytical run, standard curves for crizotinib and gemcitabine, 
and its metabolite difluorodeoxyuridine (dFdU) were prepared in either whole blood or cell culture 
medium. Separate extractions for gemcitabine/dFdU and crizotinib were just not possible because the 
sample volume available for the mouse blood samples ranged from 5-20 µl per time point. Therefore, 
extraction using acetonitrile precipitation was used for gemcitabine and dFdU. Gemcitabine/ dFdU 
sensitivity was lower (especially for dFdU in tissues) compared to the previously published procedure but 
was linear in response across multiple days. The limit of quantification for gemcitabine was 10 ng/ml. Linear 
regression for gemcitabine was not affected by the presence of crizotinib and chromatographically all 
compounds were separated (Figure 2C). 
Tissue analysis 
Preparation of a standard curve within a tissue matrix was not always feasible due to the lack of 
sufficient tissue from untreated mice. Therefore cell culture medium was compared with blank mouse 
tissue (heart), which was available in sufficient quantity for the validation procedure.  Both were prepared 
as per protocol. Separate standard curves were prepared by spiking with crizotinib and gemcitabine 
dilutions in acetonitrile:water (5:1). No difference was observed. Therefore, for all tissue analysis cell 
culture medium was used for the standard matrix. 
Recovery of crizotinib, gemcitabine and dFdU was verified using the extracted tissue of the combination 
treated animal, by testing whether subsequent extraction would yield any detectable drug. Therefore, 
tissues were extracted with acetonitrile:water (5:1) for a second and third time. After analysis no crizotinib, 
gemcitabine or dFdU could be observed within the second and third extracts, indicating that close to 100 % 
had been recovered on the first extraction (data not shown). 
Results 
Whole blood analysis 
Limited sampling was performed at 1 and 2 hour, since the peak concentration of gemcitabine was 
expected around these time intervals [10,11]. Whole blood analysis of the treated animals demonstrated 
measurable concentrations for gemcitabine (2 h:  1.0 ± 0.3 µM), dFdU (2 h:  5.6 ± 1.4 µM) and crizotinib (2 
h: 2.4 ± 0.8 µM) (Figure 3). 
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Tissue analysis 
Gemcitabine was found in all tissues that could be analyzed, when given alone or in combination. The 
highest levels were found in skin and spleen. The concentration in the brain was relatively high compared 
to the other tissue types and even comparable to liver (Figure 4), showing a good brain penetration of 
gemcitabine. However, the primary metabolite of gemcitabine, dFdU, was not detectable for this group of 
samples. This was most likely due to the lack of sensitivity of uridine based compounds to mass 
spectrometric detection under the chromatographic conditions used, since we did not use the optimal LC-
MS conditions as used earlier for tissues [14]. In the combination the highest levels of gemcitabine were 
found in the same tissues as at single drug treatment, with increased drug levels in blood, but lower levels 
in lung and brain (Figure 4).   
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Figure 3. Concentrations of crizotinib, gemcitabine and dFdU in whole mouse blood. Blood was taken at 1 and 
2 h after drug administration. Values are means ± SD of 3 animals. 
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Figure 4. Tissue analysis (at 2 hour after drug administration) of gemcitabine at single drug administration (A) 
and in combination with crizotinib (B). Values are means ± SD of 3 animals. 
 At single treatment crizotinib accumulated at high levels in lung, liver and pancreatic tissues, and at very 
low levels in the brain (100-fold lower) (Figure 5A). In the combined treatment crizotinib (pmol/mg tissue) 
was also found in all major tissues at varying concentrations; intestine demonstrated the highest levels 
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(1084) followed by liver (215), lung (172) and kidney (167). In addition, crizotinib was found in the spleen 
(133), skin (28), heart (34), pancreas (48) and brain (4). Crizotinib demonstrated an increased accumulation 
compared to the single treatment in 4 of 5 tissues tested (Figure 5B and Table 1). 
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 Figure 5. Tissue analysis (at 2 hour after drug administration) of crizotinib at single drug administration (A) 
and in combination with gemcitabine (B). Values are means ± SD of 3 animals. 
 
Table 1. Effect of combination treatment on drug levels in normal tissues, the pancreatic tumor 
and blood.  
 Blood Pancreas Liver Lung Brain Skin Tumor 
Crizotinib 1.4 1.4 2.0 0.8 4.5 1.6 1.4 
Gemcitabine 2.0 1.3 0.4 0.2 0.2 1.2 1.3 
Values are ratios of the combination versus single drug. Tumor data are from [7] 
Discussion 
Tissue distribution of crizotinib alone and of the gemcitabine and crizotinib combination has not been 
reported previously. Only limited data are available for gemcitabine distribution in the range of tissues we 
have tested. Early data on gemcitabine tissue accumulation were obtained using radioactively labeled drug 
[12,13]; however, these data does not differentiate between gemcitabine and dFdU, which could 
overestimate the tissues exposure to gemcitabine. As expected, gemcitabine is accumulated into all tested 
tissues, in agreement with previous results in humans and animals [14-17], as also shown with 19F-NMR15. 
The use of the sensitive LC-MS/MS technique enabled acquisition of reproducible blood pharmacokinetics 
for all three compounds (crizotinib, gemcitabine and dFdU) simultaneously without interference [8,9], but 
tissue analysis of dFdU was not possible since we had to adapt the protocol to have one extraction 
procedure for all drugs. Using the optimal LC-MS/MS procedure for dFdU we could demonstrate 
accumulation of dFdU in human tissue [14]. Whole blood analysis proved consistent with expected 
pharmacokinetics of gemcitabine 1 and 2 hours after dosing [10,11]. Gemcitabine levels demonstrated a 
rapid decrease in concentration over the 2 hour time period corresponding to an increase in observable 
dFdU in agreement with an earlier pharmacokinetic study in mice [11]. For crizotinib, literature reported 
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data are limited, but since the methodology was adequate for blood and tissue pharmacokinetics of 
gemcitabine as well as blood crizotinib, it can be assumed that the crizotinib results also reflect the true 
situation. Crizotinib demonstrated an elevated concentration after 1 hour which was maintained after 2 
hours indicating a steady state condition had probably been reached.  
Crizotinib accumulated into all tested tissues at levels consistent with therapeutic concentrations, 
except for brain. Crizotinib accumulation in the brain tissue has not been previously reported, but low 
levels were expected since it is a good substrate for efflux pumps [18]. Hence, crizotinib does not show 
efficacy in patients with either brain tumors of liver metastases [19].  
The combination of crizotinib with gemcitabine appears to enhance crizotinib exposure in the tissues of 
the pancreas, liver, brain and skin. The accumulation of crizotinib in the orthotopic tumor was about 
37.4±30.3 pmol/mg tissue, while that of gemcitabine was about 5.84±2.41 pmol/mg tissue, demonstrating 
excellent tumor uptake. c-Met overexpression is observed in tumors from many different tissues such as 
brain, kidney, ovarian, breast and gastrointestinal cancers [4,20]. The use of crizotinib might be considered 
as an additional resource in these areas, especially in combination with gemcitabine. Crizotinib also appears 
to enhance the exposure of pancreas and skin towards gemcitabine, possibly by inhibiting the gemcitabine 
degradation enzyme cytidine deaminase [3]. The high accumulation of crizotinib in tissues might not reflect 
the actually accumulation in cells, particularly in the cytoplasm. Earlier we demonstrated in cancer cell lines 
that crizotinib might concentrate in lysosomes [18], similar to sunitinib [21]. Hence, in tissue with a high 
content of lysosomes the accumulation might be a lysosomal accumulation. 
It is not clear what these data mean in view of toxicology, however, in general crizotinib is tolerated 
well, although the drug may induce gastrointestinal toxicity, edema and visual impairment [5,22,23]. The 
toxicity of gemcitabine in patients is predominantly hematological [24] which is in line with the high 
concentration observed in the spleen. 
These results clearly show that distribution of crizotinib and gemcitabine occurs over a broad range of 
tissue types achieving therapeutic concentrations for both drugs. The accumulation in specific tissues 
(spleen, intestine) seems to be in line with the observed toxicity in patients. Moreover, in certain tissue 
types crizotinib appears to enhance the exposure to gemcitabine suggesting the need for further 
development of this combination, especially with regards to PDAC. 
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